← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
rebamipide
A02BX14
Adult Dosing
- Gastric ulcer: 100 mg orally three times daily (morning, evening, and before bed)
- Gastric mucosal lesions (erosion, bleeding, redness, edema): 100 mg orally three times daily
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of gastric ulcers
- Improvement of gastric mucosal lesions associated with acute gastritis and acute exacerbation of chronic gastritis
Mechanism of Action
- Enhances mucosal defense mechanisms by increasing gastric mucus and prostaglandin E2 synthesis
- Scavenges free radicals and inhibits inflammatory cytokine production
- Promotes gastric ulcer healing and protects the gastric mucosa from various ulcerogenic agents
Contraindications
- Hypersensitivity to rebamipide or any component of the formulation
Adverse Reactions
- Nausea and vomiting
- Constipation or diarrhea
- Abdominal pain
- Hepatic dysfunction (elevated AST, ALT, gamma-GTP)
- Leukopenia and granulocytopenia (rare)
Drug Interactions
- No clinically significant pharmacokinetic drug interactions have been definitively established
- Generally considered to have a low potential for cytochrome P450-mediated drug interactions
Curated Content: Needs Vetting Before Put to Clinical Use